Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer

Histology and Histopathology

Volumn 23, Issue 8, 2008, Pages 917-923

  Alakus, H ^a   Grass, G ^a   Hennecken, J K ^a   Bollschweiler, E ^a   Schulte, C ^a   Drebber, U ^a   Baldus, S E ^b   Metzger, R ^a   Holscher A H ^a   Monig S P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Gastric carcinoma; Immunohistochemistry; Matrix metalloproteinase

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GASTRECTOMY; GERMANY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GASTRECTOMY; GERMANY; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 46249122672     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ala-aho R. and Kahari V.M. (2005). Collagenases in cancer. Biochimie 87, 273-286.
2. Allgayer H., Babic R., Beyer B.C., Grutzner K.U., Tarabichi A., Schildberg F.W. and Heiss M.M. (1998). Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 55, 152-160.
3. Chen W.T. (1992). Membrane proteases: roles in tissue remodeling and tumour invasion. Curr. Opin. Cell Biol. 4. 802-809.
4. Curran S., Dundas S.R., Buxton J., Leeman M.F., Ramsay R. and Murray G.I. (2004). Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin. Cancer Res. 10, 8229-8234
5. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Nesland J.M., Berner A., Bryne M. and Reich R. (1999). High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 17, 799-808.
6. Egeblad M. and Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
7. Emmert-Buck M.R., Emonard H.P., Corcoran M.L., Krutzsch H.C., Foidart J.M. and Stetler-Stevenson W.G. (1995). Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett. 364, 28-32.
8. Grignon D.J., Sakr W., Toth M., Ravery V., Angulo J., Shamsa F., Pontes J.E., Crissman J.C. and Fridman R. (1996). High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 56, 1654-1659.
9. Howard E.W., Bullen E.C. and Banda M.J. (1991). Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 266, 13070-13075.
10. Joo Y.E., Seo K.S., Kim H.S., Rew J.S., Park C.S. and Kim S.J. (2000). Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig. Dis. Sci. 45, 114-121.
11. Kanayama H., Yokota K., Kurokawa Y., Murakami Y., Nishitani M. and Kagawa S. (1998). Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82, 1359-1366.
12. Koyama S. (2004). Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig. Dis. Sci. 49, 1621-1630.
13. Kubben F.J., Sier C.F., van Duijn W., Griffioen G., Hanemaaijer R., van de Velde C.J., van Krieken J.H., Lamers C.B. and Verspaget H.W. (2006). Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br. J. Cancer. 94, 1035-1040.
14. Leone A., Flatow U., King C.R., Sandeen M.A., Margulies I.M., Liotta L.A. and Steeg P.S. (1991). Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65, 25-35.
15. Liotta L.A., Steeg P.S. and Stetler-Stevenson W.G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
16. Monig S.P., Baldus S.E., Hennecken J.K., Spiecker D.B., Grass G., Schneider P.M., Thiele J., Dienes H.P. and Holscher A.H. (2001). Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 39, 597-602.
17. Mrena J., Wiksten J.P., Nordling S., Kokkola A., Ristimaki A. and Haglund C. (2006). MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J. Clin. Pathol. 59, 618-623.
18. Murray G.I., Duncan M.E., Arbuckle E., Melvin W.T. and Fothergill J.E. (1998). Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43, 791-797.
19. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. (1998). Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185, 256-261.
20. Nomura H., Sato H., Seiki M., Mai M. and Okada Y. (1995). Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55, 3263-3266.
21. Nuovo G.J., MacConnell P.B., Simsir A., Valea F. and French D.L. (1995). Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55, 267-275.
22. Shim K.N., Jung SA, Joo Y.H. and Yoo K. (2007). Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J. Gastroenterol. 42, 120-128.
23. Sier C.F., Kubben F.J., Ganesh S., Heerding M.M., Griffioen G., Hanemaaijer R., van Krieken J.H., Lamers C.B. and Verspaget H.W. (1996). Tissue levels of matrix metalloproteinases MMP-2 and MMP- 9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 74, 413-417.
24. Stetler-Stevenson W.G., Krutzsch H.C., Wacher M.P., Margulies I.M. and Liotta L.A. (1989). The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J. Biol. Chem. 264, 1353-1356.
25. Upadhyay J., Shekarriz B., Nemeth J.A., Dong Z., Cummings G.D., Fridman R, Sakr W., Grignon D.J. and Cher M.L. (1999). Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin. Cancer Res. 5, 4105-4110.
26. Vasala K., Paakko P. and Turpeenniemi-Hujanen T. (2003). Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62, 952-957.
27. Zhang J.F., Zhang Y.P., Hao F.Y., Zhang C.X., Li Y.J. and Ji X.R. (2005). DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. World J. Gastroenterol. 11, 5592-5600.
28. Zhou Y., Yu C., Miao X., Tan W., Liang G., Xiong P., Sun T. and Lin D. (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25, 399-404.